Abiopharma

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001213900-26-049639 <b>Size:</b> 54 KB

New Form EFFECT - AMICUS THERAPEUTICS, INC. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 9999999995-26-001363 <b>Size:</b> 1 KB

New Form EFFECT - Nexentis Technologies Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 9999999995-26-001385 <b>Size:</b> 2 KB

New Form EFFECT - PAVmed Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 9999999995-26-001387 <b>Size:</b> 1 KB

New Form EFFECT - AMICUS THERAPEUTICS, INC. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 9999999995-26-001365 <b>Size:</b> 1 KB

Financial Statements and Related Announcement: Notification of Results Release

Publication date of financial statements for the first quarter of 2026 on 20.5.26

General Announcement: Monthly Update Pursuant to Catalist Rule 704(22)

21shares Partners with Kaiko Indices to Enhance Pricing Precision Across European Single-Asset Crypto Suite

Change in holdings of interested parties/officers

Letter of the Commissioner of Capital Market, Insurance and Savings dated 29.4.26 regarding the dismissal of Avraham Dotan and others, divided

General Announcement: Transaction in own shares

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

Fulfillment of Conditions Precedent for Completion of the BUYME Transaction

CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF its outstanding GBP Undated Deeply Subordinated Additional Tier 1 Fixed Rate Resettable Notes issued in June 2021 (ISIN: Rule 144A: XS2353100402 and Regulation S: XS2353099638)